A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX)

Health Technology Assessment

Volumn 14, Issue 23, 2010, Pages

  Cross, J ^a   Elender, F ^a   Barton, G ^b   Clark, A ^b   Shepstone, L ^b   Blyth, A ^a   Bachmann, M ^b   Harvey, I ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DYSPNEA; ECONOMICS; EXERCISE TEST; FEMALE; HEALTH STATUS INDICATOR; HUMAN; LUNG FUNCTION TEST; MALE; MANIPULATIVE MEDICINE; METHODOLOGY; MIDDLE AGED; PSYCHOMETRY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPUTUM; TREATMENT OUTCOME; UNITED KINGDOM; VERY ELDERLY; WALKING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DYSPNEA; EXERCISE TEST; FEMALE; GREAT BRITAIN; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MUSCULOSKELETAL MANIPULATIONS; PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME; WALKING;

EID: 77953448092     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14230     Document Type: Article

References (89)

1. [No authors listed.] COPD prevalence. Bandolier 2003;113:3.
2. The National Collaborating Centre for Chronic Conditions. Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Appendix D: Economic costs of COPD to the NHS. Thorax 2004;59:192-4.
3. Chief Medical Officer. On the state of the public health: annual report of the Chief Medical Officer of the Department of Health 2004. London: Department of Health 2005.
4. Dixon J, Damiani M. COPD medical admissions in the UK, 2000/01-2001/02. London: The King's Fund; 2004.
5. Tydeman DE, Cross JL. Respiratory physiotherapy manual techniques: Review of the literature. Physiotherapy 2001;87:603.
6. Wollmer P, Ursing K, Midgren B, Eriksson L. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. Eur J Respir Dis 1985;66:233-9.
7. Mazzocco MC, Owens GR, Kirilloff RN, Rogers RM. Chest percussion and postural drainage in patients with bronchiectasis. Chest 1985;88:360-3.
8. Webber BA, Parker RA, Hofmeyr J, Hodson M. Evaluation of self percussion during postural drainage using the forced expiration technique. Physiother Pract 1985;1:42-5.
9. Sutton PP, Lopez-Vidriero MT, Pavia D, Newman SP, Clay MM, Webber B, et al. Assessment of percussion, vibratory-shaking and breathing exercises in chest physiotherapy. Eur J Respir Dis 1985;66:147-52.
10. Van Der Schans CP, Piers DA, Posta DS. Effect of manual percussion on tracheobronchial clearance in patients with chronic airflow obstruction and excessive tracheobronchial secretion. Thorax 1986;41:448-52.
11. Rossman CM, Waldes R, Sampson D, Newhouse MT. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am Rev Respir Dis 1982;126:131-5.
12. Brown PM, Manfreda J, McCarthy DS, MacDonald S. The effect of mechanical vibration in patients with acute exacerbations of chronic obstructive pulmonary disease. Physiother Can 1987;39:371-4.
13. Gallon A. Evaluation of chest percussion in the treatment of patients with copious sputum production. Respir Med 1991;85:45-51.
14. Connors A, Hammon W, Martin R, Rogers R. Chest physical therapy: the immediate effect on oxygenation in acutely ill patients. Chest 1980;78:559-64.
15. De Boeck C, Zinman R. Cough versus chest physiotherapy. Am Rev Respir Dis 1984;129:182-4.
16. Campbell A, O'Connell J, Wilson F. The effect of chest physiotherapy upon the FEV1 in chronic bronchitis. Med J Aust 1975;1:33-5.
17. Newton D, Stephenson A. Effect of physiotherapy on pulmonary function. Lancet 1978;2:228-30.
18. May D, Munt P. Physiologic effects of chest percussion and postural drainage in patients with stable chronic bronchitis. Chest 1979;75:29-32.
19. Feldman J, Traver GA, Taussig LM. Maximal expiratory flows after postural drainage. Am Rev Respir Dis 1979;119:239-45.
20. Rivington-Law BA, Epstein SW, Thompson GL, Pulm R, Corey PN. Effect of chest wall vibration on pulmonary function in chronic bronchitis. Chest 1984;85:378-81.
21. Bateman J, Daunt K, Newman S, Pavia S, Clarke S. Regional lung clearance of excessive bronchial secretions during chest physiotherapy in patients with stable chronic airways obstruction. Lancet 1979;1:294-7.
22. Bateman J, Newman S, Daunt K, Sheahan N, Pavia D, Clarke S. Is cough as effective as chest physiotherapy in the removal of excessive tracheobronchial secretions? Thorax 1981;36:683-7.
23. Buscaglia AJ, St. Marie MS. Oxygen saturation during chest physiotherapy for acute exacerbation of severe chronic obstructive pulmonary disease. Respir Care 1983;28:1009-13.
24. Holland A, Button B. Is there a role for airway clearance techniques in chronic obstructive pulmonary disease? Chron Respir Dis 2006;3:83-91.
25. McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidencebased clinical practice guidelines. Chest 2006;129(Suppl. 1):250S-259S.
26. Garrod R, Lasserson T. Role of physiotherapy in the management of chronic lung diseases: an overview of systematic reviews. Respir Med 2007;101:2429-36.
27. National Service Frameworks COPD. Available at: http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/COPD/DH_085153 (accessed 25 April 2009).
28. O'Reilly J, Williams AE, Ledger G, Rice L. Health Utility burden of exacerbation in COPD requiring admission to hospital as measured by EQ-5D. American Thoracic Society 99th International Conference, 16-21 May 2003, Seattle, WA, USA.
29. Stahl E. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes 2003;1:18.
30. Singh SJ, Sodergren SC, Hyland ME, Williams J, Morgan MD. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med 2001;95:71-7.
31. Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005;23:345-63.
32. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006;7:109.
33. Jones P, Calverley P, Larsson T, Peterson S. St George's Respiratory Questionnaire (SGRQ) scores may help identify COPD patients at increased risk of death over 1 year. Fifth International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5), Birmingham, UK, 28-30 June 2006.
34. Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age Ageing. 2005;34:491-6.
35. Bausewein C, Farquhara M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007;101:3339-410.
36. Leidy NK, Schmier JK, Jones MKJ, Lloyd J, Rocchicciou K. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale Respir Med 2003;97:59-70.
37. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997;35:1095-108.
38. Harper R, Brazier JE, Waterhouse JC, Walters SJ, Jones NM, Howard P. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997;52:879-87.
39. Rutten-van Molken PMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does Quality of life of COPD patients as measured by the generic EuroQoL five-dimension questionnaire differentiate between COPD severity stages? Chest 2006;130:1117-28.
40. Cecins NM, Jenkins SC, Pengelley J, Ryan G. The active cycle of breathing techniques - to tip or not to tip? Respir Med 1999;93:660-5.
41. Sutton PP, Parker RA, Webber BA, Newman SP, Garland N, Lopez-Vidriero MT, et al. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy Eur Respir J 1983;64:62-8.
42. Medical Research Council, Committee on the Aetiology of Chronic Bronchitis. Standardised questionnaires on respiratory symptoms. Br Med J 1960;2:1665.
43. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54: 581-6.
44. Wedzicha JC, Paul EA, Garrod R, Garnham R, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1999;54:581-6.
45. Butland RJA, Pang J, Gross ER, et al. Two, Six and Twelve Minute Walking Tests. Br Med J 1982;284:1607-8.
46. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk test used in the cardiorespiratory domain. Chest 2001;119;1:256-70.
47. Drummond MF, Sculpher MJ, Torrance GW, O'Brian BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd edn. New York, NY: Oxford University Press; 2005.
48. Barton GR, Sach T, Jenkinson C, Avery A, Doherty M, Muir KR. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008;6:51.
49. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl. 1):1-232.DOI:10.1136/thx.2004.022707.
50. American Association for Respiratory Care (AARC). Clinical practice guideline, postural drainage therapy. Respir Care 1991;36:1418-26.
51. Thoracic Society. ATS Statement: Guidelines for the Six-minute Walk Test. Am J Respir Crit Care Med 2002;166:111-17.
52. White RJ, Rudkin ST, Harrison ST, Day KL, Harvey IM. Pulmonary rehabilitation compared with brief advice for severe COPD. J Cardiopulm Rehabil Prev 2002;22:338-44.
53. Royston P. Multiple imputation of missing values: update of ice. Stata J 2005;5:527-36.
54. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ: John Wiley & Sons; 1987.
55. Molenberghs G, Kenward MG. Missing data in clinical studies. London: Wiley; 2007.
56. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-61.
57. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
58. Curtis LA. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2008.
59. Department of Health. NHS reference costs 2006/07. London: Department of Health.
60. Brooks R. Euroqol: the current state of play. Health Policy 1996;37:53-72.
61. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003;12:1061-7.
62. Schafer JL. Multiple imputations: a primer. Stat Methods Med Res 1999;8:3115.
63. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96.
64. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S68-S80.
65. Barton GR, Briggs AH, Fenwick EA. Optimal costeffective decisions: the role of the cost-effectiveness acceptability curve (CEAC), cost-effectiveness acceptability frontier (CEAF) and expected value of perfect information (EVPI). Value Health. 2008;11:886-97.
66. Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
67. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.
68. Briggs AH, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92.
69. Day SJ, Altman DG. Statistics Notes: Blinding in clinical trials and other studies. BMJ 2000;321:504.
70. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 2003;52(Suppl. 5):S2.
71. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez- Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387.
72. Fruchter O. Predictors of long-term survival in elderly patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Respirology 2008;13:851-5.
73. Yohannes AM, Connolly MJ. A national survey: percussions, vibration, shaking and active cycle breathing techniques in patients with acute exacerbations of chronic obstructive pulmonary disease. Physiotherapy 2007;93:110-13.
74. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93.
75. Jones PW, Quirk FH, Baveystock CM. The St. George's Questionnaire. Respir Med 1991;85(Suppl.):25-31.
76. Jones PW, Group NSQoLS. Quality of life, symptoms, and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Eur J Respir Dis 1994;7:55.
77. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Health Econ 1999;18:341-64.
78. Claxton K, Sculpher MJ, Drummond M. A national framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002:360:711-15.
79. Richardson G, Bloor K, Williams J, Russell I, Durai D, Cheung WY, et al. Cost effectiveness of nurse delivered endoscopy: findings from randomised multi-institution nurse endoscopy trial (MINuET). BMJ 2009:338:b270.
80. Wong A, Gan W, Burns J, Sin D, van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J 2008;15:361-364
81. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.
82. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, et al. Cost-effectiveness of computerised cognitive behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004;185:55-62.
83. Byford S, Knapp M, Greenshields J, Ukoumunne OC, Jones V, Thompaon S, et al. Costeffectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med 2003;33:977-86.
84. Beecham J, Sleed M, Knapp M, Chiesa M, Drahorad C. The costs and effectiveness of two psychosocial treatment programmes for personality disorder: a controlled study. Eur J Psychiatry. 2006;21:102-9.
85. Van Roijen LH, Van Straten A, Rutten F, Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br J Psychiatry 2006;188:323-9.
86. McCrone P, Risedale L, Darbishare L, Seed P. Costeffectiveness of cognitive behavioural therapy, graded exercise and usual care for patients with chronic fatigue in primary care. Psychol Med 2004;34:991-9.
87. Severens JL, Prins JB, Van der Wilt GJ, Van der Meer JWM, Bleijenber G. Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. Q J Assoc Phys 2004;97:153-61.
88. Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis: economic results. Osteoarthritis Cartilage 2002;10:518-27.
89. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease - the DOSE Index. Am J Respir Crit Care Med. 2009;180:1189-95.